Kite Pharma
Kite’s CAR T-Cell Therapy Data Show Real-World Patient Benefit and Durable Response Across Difficult-to-Treat Blood Cancers
Largest Real-World (RW) Analyses of Yescarta® (Axicabtagene Ciloleucel) Show 74% Overall Survival (OS) at 12 Months in Second-Line Relapsed/Refractory Large B-cell Lymphoma (LBCL), Consistent with OS Reported in Pivotal ZUMA-7 Study, across Broader Patient Populations Tecartus® (Brexucabtagene Autoleucel) Demonstrates Prolonged Median Overall Survival of 25.6 Months in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (B-ALL) after more than...
Kite Presents New Data on Patient Outcomes with CAR T-Cell Therapy at the 7th European CAR T-Cell Meeting, 6-8 February, Strasbourg, France
6 February 2025 -- Stockley Park, UK -- Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. Data from Italy demonstrate Kite’s...
Longest Follow-Up Data Reported for Kite’s Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Only CAR T to Demonstrate Prolonged Overall Survival After Five Years Follow-Up in Relapsed/Refractory Mantle Cell Lymphoma ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients Real-World Evidence Analysis Shows High Effectiveness and Safety Profile Consistent with ZUMA-3 in Broader Relapsed/Refractory B-Cell Precursor Acute...
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous evidence on the association between timely infusion and Patient outcomes Preliminary results supporting safety and feasibility of outpatient administration of axicabtagene ciloleucel and Tecartus (brexucabtagene...
Kite Receives European Medicines Agency Approval of Safety Monitoring Variation for CAR T-Cell Therapy Portfolio
In-hospital patient monitoring for adverse events reduced from ten to seven days following CAR T-cell therapy infusion 6 June 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today announced that the European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen...
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit was seen regardless of age, prior treatment or subsequent allogeneic stem cell transplant status Data being presented at the 2024 American Society of Clinical Oncology...
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability of response of more than 12 months Data presented orally at the 2024 American Society Of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024 --...
KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy
Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma Encore oral presentation from the phase 1 study of Anitocabtagene autoleucel (anito-cel) in relapsed/refractory multiple myeloma (R/R MM); trial design for phase 3 iMMagine-3 pivotal...
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab, to be Presented Pilot Study Results of Yescarta (Axicabtagene Ciloleucel) in Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas, an Area of Unmet Clinical...
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK -- Kite, a Gilead Company, announced results from a comparative analysis of outcomes for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who received Tecartus (brexucabtagene...
